CSL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.5 USD | +1.17% |
|
+2.31% | +5.47% |
| Jul. 08 | Australia shares end lower; eyes on key data points this week | RE |
| Jun. 25 | Finland to start bird flu vaccinations for humans | RE |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52.59 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +5.47% | 97.06B | - | ||
| +7.24% | 41.54B | A- | ||
| -8.49% | 33.89B | B- | ||
| +83.27% | 29.78B | A | ||
| -12.97% | 15.63B | C | ||
| -0.80% | 13.66B | B- | ||
| -12.22% | 11.43B | D+ | ||
| +173.60% | 10.37B | D | ||
| +4.64% | 9.14B | B+ | ||
| -55.33% | 8.64B | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CSL Stock
- CSLLY Stock
- Ratings CSL Limited
